RNS Number: 5472 D Diurnal Group PLC 26 June 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

Richard Bungay, Chief Financial Officer, purchased 8,000 Ordinary Shares at a price of 29.75 pence per Ordinary Share. Founded in 2004, Diurnal is a UK- based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal...

RNS Number: 0864 D Diurnal Group PLC 21 June 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 0862 D Diurnal Group PLC 21 June 2019 Correction: The following amendment has been made to the' Holding in Company' announcement released on 18 June 2019 at 17:30 under RNS No 6729 C.. The changes relate to sections 7, 8 and 9 in the Holding in Company announcement. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider...

RNS Number: 0316 D Diurnal Group PLC 21 June 2019. Founded in 2004, Diurnal is a UK- based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. RNS is approved by the Financial Conduct Authority to act...

RNS Number: 8070 C Diurnal Group PLC 19 June 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 6729 C Diurnal Group PLC 18 June 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

Martin Whitaker, Chief Executive Officer, subscribed for 19,230 ordinary shares of 5 pence each in Diurnal Group plc at a price of 26 pence per Ordinary Share. Richard Bungay, Chief Financial Officer, subscribed for 19,230 Ordinary Shares at a price of 26 pence per Ordinary Share. Peter Allen, Chairman, subscribed for 84,722 Ordinary Shares at a price of 26 pence...

Richard Ross, Chief Scientific Officer and his wife, Sarah Ross, sold in aggregate 148,300 Ordinary Shares at a price of 27 pence per Ordinary Share and their respective ISAs purchased 148,300 Ordinary Shares in aggregate at a price of 27.02 pence per Ordinary Share. Founded in 2004, Diurnal is a UK- based specialty pharma company developing high quality...

RNS Number: 3518 C Diurnal Group PLC 14 June 2019 NEITHER THIS ANNOUNCEMENT NOR ANY PART OF IT CONSTITUTES AN OFFER TO SELL OR ISSUE OR THE SOLICITATION OF AN OFFER TO BUY, SUBSCRIBE FOR OR ACQUIRE ANY SECURITIES IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL AND THE INFORMATION CONTAINED HEREIN IS NOT FOR PUBLICATION OR...

Diurnal Group Plc (DNL.L) Announced that it has received valid acceptances and excess applications from Qualifying Shareholders in respect of a total of 2,229,578 Open Offer Shares pursuant to the terms of the Open Offer. This represents approximately 57.8% of the 3,857,617 Open Offer Shares. The Open Offer closed for acceptances on 13 June 2019. As a consequence and conditional on, amongst other things, Shareholder approval of the Resolutions at the General Meeting to be held later today and Admission, the company has raised gross proceeds of approximately £579,690 through the Open Offer and approximately £5.93 million (before expenses) in aggregate through the Placing and Open Offer

RNS Number: 1809 C Diurnal Group PLC 14 June 2019 NEITHER THIS ANNOUNCEMENT NOR ANY PART OF IT CONSTITUTES AN OFFER TO SELL OR ISSUE OR THE SOLICITATION OF AN OFFER TO BUY, SUBSCRIBE FOR OR ACQUIRE ANY SECURITIES IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL AND THE INFORMATION CONTAINED HEREIN IS NOT FOR PUBLICATION OR...

RNS Number: 2236 A Diurnal Group PLC 28 May 2019 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA, THE RUSSIAN FEDERATION, THE REPUBLIC OF IRELAND OR JAPAN OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED...

Diurnal on track to submit Market Authorisation Application in Europe in Q4 2019. "Today marks the first step in the Market Authorisation Submission process in Europe for Chronocort ®. We believe that Chronocort ® represents a valuable treatment option for patients suffering from congenital adrenal hyperplasia, in a market estimated at $250 million in...

RNS Number: 9367 X Diurnal Group PLC 02 May 2019 2 May 2019. Founded in 2004, Diurnal is a UK- based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including congenital adrenal hyperplasia and adrenal insufficiency. RNS is approved by the Financial Conduct...

RNS Number: 6188 X Diurnal Group PLC 30 April 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 6066 X Diurnal Group PLC 30 April 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 3128 X Diurnal Group PLC 26 April 2019 26 April 2019. Director Dealings and Issue of Equity. Diurnal Group plc, the specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, announces the issue and allotment of 11,022 ordinary shares of £0.05 to John Goddard, Non-Executive Director of the Company, as part of a...

RNS Number: 2909 X Diurnal Group PLC 26 April 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.